Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, OTS, CDER, FDA
Silver Spring, Maryland
Kellie Schoolar Reynolds, PharmD
Dr. Reynolds is Director of the Division of Infectious Disease Pharmacology in the Office of Clinical Pharmacology, CDER, FDA. She received her B.S. in Biochemistry from Virginia Tech, Pharm.D. from Virginia Commonwealth University, and completed a fellowship in Clinical Pharmacokinetics and Drug Development at University of North Carolina. Her work involves application of clinical pharmacology to development of antiviral and anti-infective drugs and drugs developed under the animal rule. Her interests include dose selection for sub-populations, drug interactions, risk/benefit assessment, and communication. Her work at FDA began in 1994 during a pivotal phase of HIV drug development, allowing her to experience the essential contribution of clinical pharmacology to development of drugs for a life threating disease.
Dr. Reynolds has presented on the study and interpretation of drug interactions and has published peer-reviewed articles that address drug interactions. She is a member of the Drug Interaction Working Group and Drug Interaction Labeling Working Group at FDA and is the FDA topic lead for the International Council for Harmonization Drug Interaction Working Group.
Dr. Reynolds is a past president of the American Society for Clinical Pharmacology and Therapeutics and was an associate editor for Clinical Pharmacology and Therapeutics.
Monday, November 2, 2020
2:00 PM – 3:00 PM ET